Case Study
FDA Warning Letter
40-279 CS_DeviationCaseStudy_v3c_OL.indd 2 10/26/11 4:40 PM40-279 CS_DeviationCaseStudy_v3c_OL.indd 3 10/26/11 4:40 PMResults: 40-279 CS_DeviationCaseStudy_v3c_OL.indd 4 10/26/11 4:40 PMResults: © Tunnell Consulting. All Rights Reserved